Eliglustat on Gaucher Disease Type IIIB

Inclusion Criteria: * Gaucher disease patients diagnosed by low B-glucocerebrosidase deficiency and GBA mutation . * The participant is at least 6 years old at time of enrollment. * Under stable Cerezyme dosage for at least for 3 months. * Presence of lymphadenopathy. * Patient (and/or their parent/legal guardian) is willing to participate and able to provide signed informed consent. Exclusion Criteria: * The participant is CYP2D6 ultra-rapid metabolizer. * The participant had received substrate reduction therapy for Gaucher disease within 3 months of enrollment. * The participant had any clinically significant disease other than GD, including cardiovascular (especially arrhythmia), renal, liver, pulmonary, endocrinopathy, hypokalemia, or hypomagnesemia that may confound the study result. * The participant is pregnant or lactating. * The participant is known to be allergy to Cerdelga. * The participant use drugs that will strongly inhibit CYP2D6 or CYP3A activity .